<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01375010</url>
  </required_header>
  <id_info>
    <org_study_id>AAAF2194</org_study_id>
    <secondary_id>2R01AI065200-06A1</secondary_id>
    <nct_id>NCT01375010</nct_id>
  </id_info>
  <brief_title>Vitamin D HIV Study on Postmenopausal Women</brief_title>
  <official_title>The Effect of Vitamin D Repletion on Postmenopausal Women With HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of vitamin D on measures of bone health
      and immune function in HIV infected postmenopausal women. The investigators prior research
      with this population revealed that low vitamin D levels are very common. Prior research with
      this population also revealed that Vitamin D is necessary for the body to absorb calcium and
      is important for the health of the bones. When vitamin D levels are low, there are increased
      risks of bone loss, muscle weakness, falls and fractures. Low levels of vitamin D have also
      been associated with impaired immune function. This study will help us learn whether two
      different doses of vitamin D will improve bone health and immune function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the effects of vitamin D repletion on rates of bone
      loss and indices of immune function in HIV+ postmenopausal women. Lower baseline serum
      Vitamin D levels, as assessed by measuring serum 25-hydroxyvitamin D (25-OHD) were associated
      with a trend toward more bone loss. In addition, the investigators found that despite
      providing supplements that contained approximately 600 IU vitamin D, serum 25-OHD did not
      increase during the first year. Provision of adequate calcium and vitamin D is the
      cornerstone of effective prevention and therapy of osteoporosis. HIV-infected patients may be
      at increased risk of having vitamin D deficiency because they take several medications that
      may interfere with vitamin D action. Therefore, the investigators will recruit 100 HIV
      infected postmenopausal women for this study who are on a stable antiretroviral therapy (ART)
      regimen and randomize them to receive 1000 or 3000 IU of vitamin D daily. The subjects will
      be followed closely for one year to monitor compliance and changes in bone health and immune
      function.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2011</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Bone Mineral Density (BMD)</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Percent change from baseline in BMD at lumbar spine (as measured by Dual-emission X-ray absorptiometry (DXA) scan) at 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Areal Change in Bone Mineral Density (aBMD)</measure>
    <time_frame>Baseline,12 months</time_frame>
    <description>To evaluate the change in areal BMD (aBMD) at the total hip (TH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Volumetric Bone Mineral Density (vBMD)</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>To evaluate the change in volumetric BMD (VBMD) at the Tibia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vitamin D Levels</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the change in vitamin D levels with supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Biochemical Markers</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the effect of vitamin D and calcium supplementation on biochemical markers of bone turnover and markers of inflammation. (PTH)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo vitamin D3 capsule daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 1000 IU.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2000 IU vitamin D3 daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 3000 IU.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>2000 mg QD</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>cholecalciferol-D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>An inactive treatment that is intended to provide baseline measurements for the experimental protocol of a clinical trial, in this case, the vitamin D3.</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Placebo capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin Supplements</intervention_name>
    <description>Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Vitamin supplementation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV+ African American and Latina postmenopausal women, aged 40-70, who meet the
             standard definition of menopause:

        If 50 years old or older then amenorrhea for &gt; 1year. If age 40 to 49 then amenorrhea for
        over a year and and Follicle-Stimulating Hormone (FSH) level of equal to or greater than 20
        mIU/ml; as some amenorrheic chronically ill women may have hypothalamic dysfunction and low
        FSH values, if FSH is 10 to 19, and the serum estradiol level is consistent with menopause
        less than or equal to 30pg/ml, she will be determined to be postmenopausal.

          -  On stable antiretroviral therapy (ART) for &gt;2 years

          -  Undetectable HIV RNA (viral load) at least 2 times over the past year (RNA &lt;400)

        Exclusion Criteria:

          -  Metabolic bone disease (Paget's disease, clinical osteomalacia, primary
             hyperparathyroidism, hypercalcemia)

          -  Multiple myeloma, solid tumors with metastases;

          -  Endocrinopathy (hyperthyroidism, untreated hypothyroidism, Cushing's syndrome,
             prolactin-secreting pituitary adenoma)

          -  Renal insufficiency (serum creatinine above 1.5 mg/dl)

          -  Liver disease (AST, ALT, bilirubin, total alkaline phosphatase activity &gt; twice upper
             normal limit);

          -  Intestinal disorders (celiac disease, pancreatic insufficiency, Crohn's disease,
             ulcerative colitis)

          -  Current use of glucocorticoids, anticonvulsants, anticoagulants, diuretics,
             methotrexate;

          -  Current or past use of drug therapies for osteoporosis (raloxifene, bisphosphonates,
             calcitonin, PTH). Women on estrogen are excluded. Past estrogen use is permitted if
             discontinued &gt;1 year before enrollment.

          -  If there is a history of a low trauma fracture, a T score &lt; -3 or a prevalent
             vertebral fracture on Instant Vertebral Assessmentâ„¢ (IVA), subjects will be referred
             for osteoporosis treatment as appropriate.

          -  Severe vitamin D deficiency (25-OHD level &lt;10 ng/ml) or normal baseline serum vitamin
             D (25-OHD &gt;32 ng/ml). Subjects with severe vitamin D deficiency may be referred to our
             sub-study, if all other inclusion/exclusion criteria are met.

          -  Hypercalcemia or history of calcium-containing kidney stones

          -  Known allergy/sensitivity or any hypersensitivity to components of study drugs or
             their formulations

          -  Current imprisonment or voluntary incarceration in a medical facility for psychiatric
             illness

          -  Any condition that, in the opinion of the site investigator, would compromised the
             subject's ability to participate in the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Shane, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Yin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>June 15, 2011</study_first_submitted>
  <study_first_submitted_qc>June 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2011</study_first_posted>
  <results_first_submitted>April 13, 2018</results_first_submitted>
  <results_first_submitted_qc>March 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 7, 2019</results_first_posted>
  <disposition_first_submitted>May 17, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>May 17, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 19, 2017</disposition_first_posted>
  <last_update_submitted>March 6, 2019</last_update_submitted>
  <last_update_submitted_qc>March 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Elizabeth Shane</investigator_full_name>
    <investigator_title>Professor of Medicine, Endocrinology</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Postmenopausal women</keyword>
  <keyword>Vitamin D</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group A</title>
          <description>Placebo vitamin D3 capsule daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 1000 IU.
Placebo: An inactive treatment that is intended to provide baseline measurements for the experimental protocol of a clinical trial, in this case, the vitamin D3.
Vitamin Supplements: Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).</description>
        </group>
        <group group_id="P2">
          <title>Group B</title>
          <description>2000 IU vitamin D3 daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 3000 IU.
Vitamin D3: 2000 mg QD
Vitamin Supplements: Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>HIV-infected postmenopausal African American or Hispanic women between ages 40-70 were recruited from 4 sites in New York City. All participants had serum 25-OHD â‰¥10 ng/mL and &lt; 32 ng/mL and were on stable ART for at least 2 years with 2 or more HIV RNA levels &lt;400 copies/ml within the last year prior to enrollment.</population>
      <group_list>
        <group group_id="B1">
          <title>Group A</title>
          <description>Placebo vitamin D3 capsule daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 1000 IU.
Placebo: An inactive treatment that is intended to provide baseline measurements for the experimental protocol of a clinical trial, in this case, the vitamin D3.
Vitamin Supplements: Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).</description>
        </group>
        <group group_id="B2">
          <title>Group B</title>
          <description>2000 IU vitamin D3 daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 3000 IU.
Vitamin D3: 2000 mg QD
Vitamin Supplements: Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="85"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.2" spread="4.9"/>
                    <measurement group_id="B2" value="56.5" spread="5.6"/>
                    <measurement group_id="B3" value="56.3" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Bone Mineral Density (BMD)</title>
        <description>Percent change from baseline in BMD at lumbar spine (as measured by Dual-emission X-ray absorptiometry (DXA) scan) at 12 months</description>
        <time_frame>Baseline, 12 months</time_frame>
        <population>A complete case approach was utilized for outcome in participants with BMD data at 12 months (n=69).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Placebo vitamin D3 capsule daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 1000 IU.
Placebo: An inactive treatment that is intended to provide baseline measurements for the experimental protocol of a clinical trial, in this case, the vitamin D3.
Vitamin Supplements: Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>2000 IU vitamin D3 daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 3000 IU.
Vitamin D3: 2000 mg QD
Vitamin Supplements: Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bone Mineral Density (BMD)</title>
          <description>Percent change from baseline in BMD at lumbar spine (as measured by Dual-emission X-ray absorptiometry (DXA) scan) at 12 months</description>
          <population>A complete case approach was utilized for outcome in participants with BMD data at 12 months (n=69).</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="4.4"/>
                    <measurement group_id="O2" value="-0.8" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Areal Change in Bone Mineral Density (aBMD)</title>
        <description>To evaluate the change in areal BMD (aBMD) at the total hip (TH)</description>
        <time_frame>Baseline,12 months</time_frame>
        <population>A complete case approach was utilized for outcome in participants with BMD data at 12 months (n=69).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Placebo vitamin D3 capsule daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 1000 IU.
Placebo: An inactive treatment that is intended to provide baseline measurements for the experimental protocol of a clinical trial, in this case, the vitamin D3.
Vitamin Supplements: Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>2000 IU vitamin D3 daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 3000 IU.
Vitamin D3: 2000 mg QD
Vitamin Supplements: Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).</description>
          </group>
        </group_list>
        <measure>
          <title>Areal Change in Bone Mineral Density (aBMD)</title>
          <description>To evaluate the change in areal BMD (aBMD) at the total hip (TH)</description>
          <population>A complete case approach was utilized for outcome in participants with BMD data at 12 months (n=69).</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="3.1"/>
                    <measurement group_id="O2" value="-0.8" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Volumetric Bone Mineral Density (vBMD)</title>
        <description>To evaluate the change in volumetric BMD (VBMD) at the Tibia</description>
        <time_frame>Baseline, 12 months</time_frame>
        <population>A complete case approach was utilized for secondary outcomes in participants with vBMD data at 12 months (n=69).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Placebo vitamin D3 capsule daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 1000 IU.
Placebo: An inactive treatment that is intended to provide baseline measurements for the experimental protocol of a clinical trial, in this case, the vitamin D3.
Vitamin Supplements: Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>2000 IU vitamin D3 daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 3000 IU.
Vitamin D3: 2000 mg QD
Vitamin Supplements: Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Volumetric Bone Mineral Density (vBMD)</title>
          <description>To evaluate the change in volumetric BMD (VBMD) at the Tibia</description>
          <population>A complete case approach was utilized for secondary outcomes in participants with vBMD data at 12 months (n=69).</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="2.9"/>
                    <measurement group_id="O2" value="-0.9" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Vitamin D Levels</title>
        <description>To evaluate the change in vitamin D levels with supplementation</description>
        <time_frame>12 months</time_frame>
        <population>A complete case approach was utilized for secondary outcomes in participants with data at 12 months (n=69).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Placebo vitamin D3 capsule daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 1000 IU.
Placebo: An inactive treatment that is intended to provide baseline measurements for the experimental protocol of a clinical trial, in this case, the vitamin D3.
Vitamin Supplements: Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>2000 IU vitamin D3 daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 3000 IU.
Vitamin D3: 2000 mg QD
Vitamin Supplements: Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Vitamin D Levels</title>
          <description>To evaluate the change in vitamin D levels with supplementation</description>
          <population>A complete case approach was utilized for secondary outcomes in participants with data at 12 months (n=69).</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7" spread="41.9"/>
                    <measurement group_id="O2" value="64.1" spread="68.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Biochemical Markers</title>
        <description>To evaluate the effect of vitamin D and calcium supplementation on biochemical markers of bone turnover and markers of inflammation. (PTH)</description>
        <time_frame>12 months</time_frame>
        <population>A complete case approach was utilized for secondary outcomes in participants with data at 12 months (n=69).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Placebo vitamin D3 capsule daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 1000 IU.
Placebo: An inactive treatment that is intended to provide baseline measurements for the experimental protocol of a clinical trial, in this case, the vitamin D3.
Vitamin Supplements: Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>2000 IU vitamin D3 daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 3000 IU.
Vitamin D3: 2000 mg QD
Vitamin Supplements: Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Biochemical Markers</title>
          <description>To evaluate the effect of vitamin D and calcium supplementation on biochemical markers of bone turnover and markers of inflammation. (PTH)</description>
          <population>A complete case approach was utilized for secondary outcomes in participants with data at 12 months (n=69).</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.2" spread="71.4"/>
                    <measurement group_id="O2" value="-16.8" spread="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Adverse event reporting was collected at every visit as part of the protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group A</title>
          <description>Placebo vitamin D3 capsule daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 1000 IU.
Placebo: An inactive treatment that is intended to provide baseline measurements for the experimental protocol of a clinical trial, in this case, the vitamin D3.
Vitamin Supplements: Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).</description>
        </group>
        <group group_id="E2">
          <title>Group B</title>
          <description>2000 IU vitamin D3 daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 3000 IU.
Vitamin D3: 2000 mg QD
Vitamin Supplements: Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Ischemia</sub_title>
                <description>Infarction</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rectal bleeding/ hemorrhage</sub_title>
                <description>Evidence of internal and external hemorrhoids</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney Stones</sub_title>
                <description>Asymptomatic kidney stones at baseline visit scans</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elizabeth Shane, MD</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-305-6289</phone>
      <email>es54@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

